OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Cancer is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Subscription & copyright page	276
FBXW10: a male-biased E3 ligase in liver cancer	208
Revumenib: a new era in acute leukemia treatment	167
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	161
Engineering growth factor ligands and receptors for therapeutic innovation	151
Tumor-resident microbes: the new kids on the microenvironment block	142
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	139
Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment	134
Advisory Board and Contents	131
Subscription & copyright page	122
Subscription and copyright page	118
Radiotherapy and immunotherapy: open questions and future strategies	113
Navigating life as an early career researcher	110
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	106
Engine shutdown: migrastatic strategies and prevention of metastases	103
Accessing the vasculature in cancer: revising an old hallmark	103
Leveraging circulating microbial DNA for early cancer detection	103
Onco-condensates: formation, multi-component organization, and biological functions	103
Benefits and opportunities of the transgenic Oncopig cancer model	102
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	101
Chromatin as an old and new anticancer target	98
Subscription & copyright page	97
IDH-Mutant Brain Tumors Hit the Achilles’ Heel of Macrophages with R-2-Hydroxyglutarate	93
Oncogenic competence: balancing mutations, cellular state, and microenvironment	91
Regulation of metastatic organotropism	91

Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	88
Crosstalk of T cells within the ovarian cancer microenvironment	85
Recent developments in myeloid immune modulation in cancer therapy	84
Diet, nutrient supply, and tumor immune responses	80
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	77
Chromosomal instability and aneuploidy as causes of cancer drug resistance	74
Gut microbiota – a double-edged sword in cancer immunotherapy	73
Advisory Board and Contents	73
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	66
Tumor immunology CRISPR screening: present, past, and future	64
GOT2 consider the tumor microenvironment	62
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	62
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	62
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer	61
Pannexin biology and emerging linkages to cancer	60
Cell death, therapeutics, and the immune response in cancer	60
Subscription & copyright page	59
Subscription & copyright page	58
Advisory Board and Contents	56
Advisory Board and Contents	56
β-Galactosylceramidase in cancer: friend or foe?	55
Scaling data toward pan-cancer foundation models	54
Palmitate paves the way to lung metastasis	53
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	53
Insights on ErbB glycosylation – contributions to precision oncology	52
Genetic immune escape in cancer: timing and implications for treatment	52
Cancer catecholamine conundrum	52
Clinical and translational relevance of intratumor heterogeneity	51
Inflammation: the incubator of the tumor microenvironment	51
The emerging field of oncolytic virus-based cancer immunotherapy	51
Advisory Board and Contents	50
Advisory Board and Contents	50
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	47
Advisory Board and Contents	47
Subscription and copyright page	47
Advisory Board and Contents	47
Updating cancer research with patient-focused networks	46
RHOA takes the RHOad less traveled to cancer	45
Advisory Board and Contents	45
Targeting the mitochondrial unfolded protein response in cancer: opportunities and challenges	45
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	44
Subscription & copyright page	42
Emerging mechanisms of telomerase reactivation in cancer	42
Circulating cell-free DNA-based multi-cancer early detection	41
Molecular and clinical insights into early-onset endometrial cancer	41
Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity	40
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	39
Modeling metastasis in mice: a closer look	39
Redefining precision cancer prevention to promote health equity	39
Stress granules and hormetic adaptation of cancer	39

B7-H3: a robust target for immunotherapy in prostate cancer	39
Advisory Board and Contents	38
Advisory Board and Contents	37
Leveraging space innovations for cancer breakthroughs on Earth	37
Advisory Board and Contents	37
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	36
Advisory Board and Contents	36
Dissecting liver tumor heterogeneity to improve health equity	36
Subscription & copyright page	36
Cross-dressing of dendritic cells strengthens antitumor immunity	36
Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises	35
A macrophage-neutrophil program drives mammary carcinogenesis	35
Functional heterogeneity of fibroblasts in primary tumors and metastases	34
Immune response and inflammation in cancer health disparities	34
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	34
Neoantigen-directed therapeutics in the clinic: where are we?	34
Subscription & copyright page	33
A tipping point in cancer epidemiology: embracing a life course exposomic framework	33
Advisory Board and Contents	33
Space in cancer biology: its role and implications	32
Engineered bacterial therapeutics for detecting and treating CRC	32
Cancer cell adaptability: turning ribonucleoprotein granules into targets	31
Advisory Board and Contents	31
Ferroptosis vulnerability in FLT3-mutant leukemia	31
Dying to survive: harnessing inflammatory cell death for better immunotherapy	30
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	30
Epigenetic basis and targeting of cancer metastasis	29
Clonal evolution and hierarchy in myeloid malignancies	29
Subscription & copyright page	29
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us	29
Advisory Board and Contents	29
Targeting the Mevalonate Pathway in Cancer	29
N of 1 Data Sharing: The Impact of Data Sharing within the Hematology–Oncology Drug Products Division of the US FDA	29
The development of therapy related myeloid neoplasms in childhood cancer survivors	28
Addressing the genetic/nongenetic duality in cancer with systems biology	28
Overstretched and overlooked: solving challenges faced by early-career investigators after the pandemic	27
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	27
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	27
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	26
Next-generation immunotherapies for brain metastatic cancers	25
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	24
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	24
Next-generation cancer vaccines and emerging immunotherapy combinations	24
Immunomodulation by endothelial cells: prospects for cancer therapy	24
NETscape or NEThance: tailoring anti-cancer therapy	24
Successfully targeting the cancer system with metronomics for medulloblastoma	23
Genitourinary cancer neoadjuvant therapies: current and future approaches	23
Lifileucel: the first cellular therapy approved for solid tumours	23
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	23
How cancer cells make and respond to interferon-I	22
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis	22
Deciphering the roles of ABCB5 in normal and cancer cells	22
Future perspectives on engineered T cells for cancer	22
Embracing diversity: macrophage complexity in cancer	22
Tissue architecture in tumor initiation and progression	22
Subscription & copyright page	22
GSDME: A Potential Ally in Cancer Detection and Treatment	21
Persisting cancer cells are different from bacterial persisters	21
Poised epigenetic states dictate metastatic fitness	20
Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer	20
Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance	20
Towards enhancing the predictive value of the microbiota for cancer immunotherapy	20
TET2, tumor control, and CAR T cell hyperproliferation	20
Subscription & copyright page	20
Hypoxia orchestrates the lymphovascular–immune ensemble in cancer	20
Zebrafish as a New Model to Study the Crosstalk between Tumor and Host Metabolism	20